Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial

被引：1

作者：

Eskander, Ramez ^{[1
]}

Sill, Michael ^{[2
]}

Beffa, Lindsey ^{[3
]}

Moore, Richard ^{[4
]}

Hope, Joanie ^{[5
]}

Musa, Fernanda ^{[5
]}

Mannel, Robert ^{[6
]}

Shahin, Mark ^{[7
]}

Cantuaria, Guilherme ^{[8
]}

Girda, Eugenia ^{[9
]}

Mathews, Cara ^{[10
]}

Kavecansky, Juraj ^{[11
]}

Leath, Charles ^{[12
]}

Gien, Lilian ^{[13
]}

Hinchcliff, Emily ^{[14
]}

Lele, Shashikant ^{[2
]}

Landrum, Lisa ^{[15
]}

Backes, Floor ^{[16
]}

O'Cearbhaill, Roisin ^{[17
]}

Liu, Rebecca ^{[18
]}

Hill, Emily ^{[19
]}

Thaker, Premal H. ^{[20
]}

John, Veena ^{[21
]}

Powell, Matthew ^{[20
]}

Aghajanian, Carol

机构：

[1] Univ Calif San Diego, La Jolla, CA 92093 USA

[2] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[3] Cleveland Clin, Cleveland, OH 44106 USA

[4] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

[5] Pacific Canc Res Consortium NCORP, Seattle, WA USA

[6] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[7] Thomas Jefferson Univ, Willow Grove, PA USA

[8] Georgia NCI Community Oncol Res, Atlanta, GA USA

[9] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[10] Women & Infants Hosp Rhode Isl, Providence, RI USA

[11] Kaiser Permanente, Walnut Creek, CA USA

[12] Univ Alabama Birmingham, Birmingham, AL USA

[13] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada

[14] Northwestern Univ, Chicago, IL 60611 USA

[15] Indiana Univ, Indianapolis, IN 46204 USA

[16] Ohio State Univ, Columbus, OH 43210 USA

[17] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[18] Trinity Hlth IHA Med Grp, Michigan Canc Res Consortium NCORP, Ypsilanti, MI USA

[19] Univ Iowa, Iowa City, IA USA

[20] Washington Univ St Louis, St Louis, MO USA

[21] Northwell Hlth Canc Inst, Lake Success, NY USA

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 190卷

关键词：

D O I：

10.1016/j.ygyno.2024.07.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

02 [LBA]

引用

页码：S5 / S5

页数：1

共 38 条

[31] Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial
Mirza, Mansoor Raza
Powell, Matthew A.
Lundgren, Caroline
Sukhin, Vladyslav
Pothuri, Bhavana
Gilbert, Lucy
Gill, Sarah
Ronzino, Graziana
Nevadunsky, Nicole
Kommoss, Stefan
Willmott, Lyndsay
Boere, Ingrid
Mathews, Cara Amanda
Buscema, Joseph
Teneriello, Michael
Shahin, Mark S.
Meyers, Oren
Garside, Jamie
Coleman, Robert L.
Slomovitz, Brian M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[32] IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin plus nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC
Cappuzzo, F.
McCleod, M.
Hussein, M.
Morabito, A.
Rittmeyer, A.
Conter, H. J.
Kopp, H-G.
Daniel, D.
McCune, S.
Mekhail, T.
Zer, A.
Reinmuth, N.
Sadiq, A.
Archer, V.
Lohmann, T. Ochi
Wang, L.
Kowanetz, M.
Lin, W.
Sandler, A.
West, H.
ANNALS OF ONCOLOGY, 2018, 29 : 742 - +
[33] Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Lorusso, Domenica
Mouret-Reynier, Marie-Ange
Harter, Philipp
Cropet, Claire
Caballero, Cristina
Wolfrum-Ristau, Pia
Satoh, Toyomi
Vergote, Ignace
Parma, Gabriella
Nottrup, Trine J.
Lebreton, Coriolan
Fasching, Peter A.
Pisano, Carmela
Manso, Luis
Bourgeois, Hugues
Runnebaum, Ingo
Zamagni, Claudio
Hardy-Bessard, Anne-Claire
Schnelzer, Andreas
Fabbro, Michel
Schmalfeldt, Barbara
Berton, Dominique
Belau, Antje
Lotz, Jean-Pierre
Gropp-Meier, Martina
Gladieff, Laurence
Lueck, Hans-Joachim
Abadie-Lacourtoisie, Sophie
Pujade-Lauraine, Eric
Ray-Coquard, Isabelle
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (04) : 550 - 558
[34] A province-wide retrospective comparison of pathologic response and progression-free survival in locally advanced esophagus cancer patients treated with either cisplatin-5FU (CF) or carboplatin-paclitaxel (CP) concurrent with radiation (XRT) with or without surgery.
Schellenberg, Devin
Peixoto, Renata
Lee, Andrea
Lim, Howard John
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[35] Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
Janne, Pasi A.
van den Heuvel, Michel M.
Barlesi, Fabrice
Cobo, Manuel
Mazieres, Julien
Crino, Lucio
Orlov, Sergey
Blackhall, Fiona
Wolf, Juergen
Garrido, Pilar
Poltoratskiy, Artem
Mariani, Gabriella
Ghiorghiu, Dana
Kilgour, Elaine
Smith, Paul
Kohlmann, Alexander
Carlile, David J.
Lawrence, David
Bowen, Karin
Vansteenkiste, Johan
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (18): : 1844 - 1853
[36] Overall survival [OS] results of NCIC Clinical Trials Group [CTG] BR.24: a randomized, double-blind trial of carboplatin plus paclitaxel [C plus P] with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine kinases, or placebo, in advanced non-small cell lung cancer [NSCLC]
Laurie, Scott A.
Arnold, Andrew
Shepherd, Frances A.
Dediu, Mircea
Ciuleanu, Tudor
Fenton, David
Zukin, Mauro
Goss, Glenwood
Ding, Keyue
Seymour, Lesley
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S353 - S353
[37] Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo) plus trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+advanced breast cancer (BC)
Emens, L. A.
Esteva, F. J.
Beresford, M.
Saura, C.
De laurentiis, M.
Kim, S-B.
Im, S-A.
Wang, Y.
Mani, A.
Shah, J.
Liu, H.
de Haas, S.
Patre, M.
Loi, S.
ANNALS OF ONCOLOGY, 2019, 30
[38] Effect of the thyroid transcription factor 1 expression and treatment discontinuation due to adverse events on progression-free survival in patients with advanced non-squamous non-small cell lung cancer treated with pembrolizumab plus pemetrexed and platinum chemotherapy: a Japanese four-hospital, retrospective study
Mori, Shoma
Maiguma, Takayoshi
Yoshii, Keisuke
Moriya, Yasushi
Takada, Ryo
Shinkai, Fumitaka
Haruki, Yuto
Hashimoto, Hikari
Komoto, Atsushi
Takayanagi, Kazunobu
Tamura, Koji
Okura, Yusuke
Sugiyama, Tetsuhiro
Shimada, Kenichi
AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (08):

← 1 2 3 4 →